ライフサイエンスコーパス: interleukin-1beta

1 umor necrosis factor, KC, interleukin 6, and interleukin 1beta).

2 he inflammatory factors cyclooxygenase 2 and interleukin 1beta.

3 st revealed a potential publication bias for interleukin 1beta.

4 hat is dependent on Toll-like receptor 2 and interleukin 1beta.

5 nd upregulation of pro-inflammatory cytokine interleukin-1beta.

6 hages to sense microbial signals and produce interleukin-1beta.

7 ion while still expressing a basal amount of interleukin-1beta.

8 nd release of inflammatory cytokines such as interleukin-1beta.

9 9 mumol mg(-1) ; P < 0.01) and inflammation (interleukin-1beta, 226.8 +/- 27.1 vs. 182.5 +/- 21.5 pg

10 xide (27.9%, 16.4% and 28.6%, respectively), interleukin-1beta (26.3%, 39.5% and 21.6%, respectively)

11 active protein (CRP), tumor necrosis factor, interleukin 1beta, 6, and 10, leukocyte telomere length,

12 matory cytokines (fold-change messenger RNA: interleukin-1beta = 7.6, monocyte chemoattractant protei

13 Levels of interleukin 1beta, a major proinflammatory cytokine, and

14 induces caspase-1 activation and release of interleukin-1beta, a pro-inflammatory cytokine involved

15 opathy of prematurity is induced by systemic interleukin-1beta administration, we undertake gene netw

16 The cytokines interleukin 1beta and 6 (IL-1beta, IL-6) mediate the acu

17 Neutralisation studies demonstrated that interleukin 1beta and CCL7, but not CXCL1 and CCL2, had

18 rculating levels of the cytokines leptin and interleukin 1beta and decreased peritoneal proinflammato

19 xpression of tumor necrosis factor-alpha and interleukin 1beta and improved liver histology compared

20 ntly lower pulmonary leukocyte counts, lower interleukin 1beta and interferon gamma levels, and highe

21 c levels of other proinflammatory cytokines (interleukin 1beta and interleukin 18) and the antiinflam

22 is-inducing ligand and induced expression of interleukin 1beta and interleukin 6 messenger RNAs in mo

23 se did not require the autocrine feedback of interleukin 1beta and tumor necrosis factor alpha releas

24 associated with reduced Aspergillus-induced interleukin 1beta and tumor necrosis factor alpha secret

25 vity was evaluated by measuring the level of interleukin-1beta and -18 in the supernatants of activat

26 nflammasome NLRP3, leading to the release of interleukin-1beta and -18, potent atherogenic cytokines.

27 o result in a caspase-8-driven activation of interleukin-1beta and a subsequent induction of the brai

28 g down the inflammatory response mediated by interleukin-1beta and explaining, at least in part, the

29 genase-2 expression and apoptosis, decreased interleukin-1beta and FAS concentrations, and increased

30 viously reported that this fungus suppresses interleukin-1beta and IL-18 secretion by inhibiting both

31 The cytokines interleukin-1beta and interferon-gamma contribute to bet

32 nflammatory stress, induced by the cytokines interleukin-1beta and interferon-gamma, leads to citrull

33 d in vitro to the pro-inflammatory cytokines interleukin-1beta and interferon-gamma.

34 o processing and maturation of the cytokines interleukin-1beta and interleukin-18 and a lytic form of

35 generation of the pro-inflammatory cytokines interleukin-1beta and interleukin-18 and pyroptotic cell

36 ukin-1beta did not respond to LPS early, and interleukin-1beta and interleukin-6 fluctuated although

37 Proinflammatory cytokines (interleukin-1beta and interleukin-6) and adenosine triph

38 the expression of the inflammatory cytokines interleukin-1beta and interleukin-6.

39 e processing of the proinflammatory cytokine interleukin-1beta and is implicated in many inflammatory

40 Consequently, HSCs are hyperactivated by interleukin-1beta and possibly other proinflammatory cyt

41 Group EP presented greater levels of interleukin-1beta and receptor activator of nuclear fact

42 of the cytoplasmic inflammasome to increase interleukin-1beta and thus enhance its cellular adhesion

43 inflammation (both: inflammation score; FR: interleukin-1beta and tumor necrosis factor alpha) vs. O

44 Cytokines, that is, interleukin-1beta and tumor necrosis factor-alpha from M

45 iators, such as tumor necrosis factor alpha, interleukins 1beta and 18, and brain-derived growth fact

46 atory (NLR family pyrin domain containing 3, interleukins 1beta and 6, and cysteine-cysteine chemokin

47 n of cytokines (tumor necrosis factor-alpha, interleukin-1beta) and restored interleukin-6 to control

48 y cytokines (tumor necrosis factor-alpha and interleukin-1beta), and myeloperoxidase activity followe

49 TNF-alpha, interleukin 1beta, and LPS markedly increase P-selectin

50 roinflammatory cytokines (eg, interleukin 6, interleukin 1beta, and tumor necrosis factor alpha) in c

51 ppaB p65, phospho-IkappaB kinase alpha/beta, interleukin 1beta, and tumor necrosis factor-alpha) with

52 of proinflammatory mediators interleukin-6, interleukin-1beta, and CXCL1/2 (C-X-C motif ligand 1/2).

53 pression of inducible nitric oxide synthase, interleukin-1beta, and interleukin 1 receptor antagonist

54 locyte-macrophage colony-stimulating factor, interleukin-1beta, and interleukin-7) as well as soluble

55 rospinal fluid tumor necrosis factor -alpha, interleukin-1beta, and interleukin-8 in a temporal manne

56 ation of monocyte chemoattractant protein-1, interleukin-1beta, and interleukin-8 transcripts levels

57 cantly elevated tumor necrosis factor-alpha, interleukin-1beta, and RANKL in the gingival tissue comp

58 helial growth factor (VEGF), angiotensin-II, interleukin-1beta, and tumor necrosis factor alpha, stim

59 icant and massive increase of interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha in ad

60 a/beta], IL-6 [interleukin 6], and IL-1beta [interleukin 1beta]), and markers of endothelial adhesion

61 eased concentrations of active caspase-1 and interleukin-1beta are related to an increased concentrat

62 Currently approved inhibitors of interleukin-1beta are rilonacept, canakinumab, and anaki

63 nally, the role of nuclear factor-kappaB and interleukin-1beta as intermediates in this interaction w

64 1- and CD3-positive cells, the production of interleukin-1beta by CD11b- and Iba-1-positive cells, an

65 macrophage-related proinflammatory molecules interleukin 1beta, CCL5, CXCL9, and CXCL10 was increased

66 on (but not NPA) levels of interferon gamma, interleukin 1beta, CCL5/RANTES, and interleukin 10 (IL-1

67 ne aminotransferase, zonula occludens-1, and interleukin-1beta compared with HS/CR alone.

68 Y females exhibited inflammation, and plasma interleukin-1beta concentrations were increased in XY fe

69 SHV protein Fas-associated death domain-like interleukin-1beta-converting enzyme-inhibitory protein (

70 nd proinflammatory cytokines and chemokines (interleukin 1beta, CXCL1, CCL2, and CCL7) were attenuate

71 ses within hours, reflected in the localized interleukin-1beta-dependent accumulation of myeloid cell

72 Interleukin-1beta did not respond to LPS early, and inte

73 arrow reconstitution experiments reveal that interleukin-1beta enhances hematopoietic stem cell proli

74 2 or its downstream effectors, caspase-1 and interleukin-1beta, erases the ability of EpSCs to recoll

75 LRP3) inflammasome activation and downstream interleukin-1beta expression in a dose-dependent manner.

76 ndocytosis, ROS generation and increases pro-interleukin-1beta expression in macrophages.

77 Finally, ANDRO inhibited LPS-induced interleukin-1beta expression through NF-kappaB inhibitio

78 EPA treatment also reduced islet interleukin-1beta expression, a proinflammatory cytokine

79 ell proliferation, and attenuated macrophage interleukin-1beta expression.

80 P2X7 and promotes inflammasome assembly and interleukin-1beta expression.

81 its release of the pro-inflammatory cytokine interleukin-1beta from activated microglia, consistent w

82 efficiently inhibit ATP-dependent release of interleukin-1beta from human and murine monocytes by a m

83 ceptor by fractalkine induces the release of interleukin-1beta from microglia, which modulates NMDA s

84 rotein-2, keratinocyte-derived cytokine, and interleukin-1beta gene expression was not altered by hyp

85 he treatments also reduced concentrations of interleukin-1beta, granulocyte colony-stimulating factor

86 The proinflammatory cytokine, interleukin-1beta, has been linked to hemolytic uremic s

87 ivating proinflammatory cytokines, including interleukin 1beta (IL-1beta) and IL-18.

88 d early expression of inflammatory cytokines interleukin 1beta (IL-1beta) and IL-6 by human myeloma m

89 tokines such as tumor necrosis factor (TNF), interleukin 1beta (IL-1beta) and interleukin 6 (IL-6).

90 -1, which induces maturation of the cytokine interleukin 1beta (IL-1beta) and pyroptotic cell death.

91 in the cytoplasm triggers the production of interleukin 1beta (IL-1beta) as an antiviral host respon

92 Interleukin 1beta (IL-1beta) is critical for the in vivo

93 obacteriales, and Enterobacteriaceae and the interleukin 1beta (IL-1beta) level; the relative abundan

94 We examined the in vitro effects of IL-6 and interleukin 1beta (IL-1beta) on peripheral blood T-cell

95 ndent inflammasome activation, which induces interleukin 1beta (IL-1beta) release and reduces interle

96 Interleukin 1beta (IL-1beta) secretion by macrophage req

97 gnificant difference was detected: Levels of interleukin 1beta (IL-1beta) were lower in dengue-infect

98 In this study, we show that interleukin 1beta (IL-1beta), a proinflammatory cytokine

99 6), tumor necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta), and monocyte chemotactic p

100 roinflammatory cytokines type I interferons, interleukin 1beta (IL-1beta), and tumor necrosis factor

101 rived SHP-2 was crucial for the induction of interleukin 1beta (IL-1beta), IL-6 and IL-23 and anti-fu

102 e in levels of the proinflammatory cytokines interleukin 1beta (IL-1beta), IL-6, and tumor necrosis f

103 ichlamydial and contained elevated levels of interleukin 1beta (IL-1beta), IL-6, IL-10, and beta inte

104 Prg2 (major basic protein) as well as lower interleukin 1beta (IL-1beta), IL-6, IL-17A, granulocyte

105 e of expression of proinflammatory mediators interleukin 1beta (IL-1beta), IL-8, and MMP-9 increased

106 ncreased expression of inflammatory cytokine interleukin 1beta (IL-1beta), IL-8, and TNF-alpha genes

107 Secretion of interleukin 1beta (IL-1beta), in response to inflammasom

108 cytokines tumor necrosis factor (TNF) alpha, interleukin 1beta (IL-1beta), interleukin 18, and interl

109 nal tumor necrosis factor-alpha (TNF-alpha), interleukin 1beta (IL-1beta), intracellular adhesion mol

110 he activation of caspase 1 and production of interleukin 1beta (IL-1beta).

111 l secretion of the pro-inflammatory cytokine interleukin 1beta (IL-1beta).

112 d the synthesis of cyclooxygenase-2 (COX-2), interleukin-1beta (IL-1beta) and fibroblast growth facto

113 A2 secreted significantly smaller amounts of interleukin-1beta (IL-1beta) and IL-18 and had a defect

114 ctivates Caspase-1, leading to maturation of interleukin-1beta (IL-1beta) and IL-18 and induction of

115 rt fast-kinetics processing and secretion of interleukin-1beta (IL-1beta) and IL-18 by the NLRP3 infl

116 es the activity of caspase-1 and cleavage of interleukin-1beta (IL-1beta) and IL-18 into mature molec

117 aturation of the pro-inflammatory cytokines, interleukin-1beta (IL-1beta) and IL-18, and cell death.

118 irect activation of caspase-1, generation of interleukin-1beta (IL-1beta) and IL-18, and pyroptotic c

119 asome activates caspase-1 and the release of interleukin-1beta (IL-1beta) and IL-18, and several infl

120 ction of essential proinflammatory cytokines interleukin-1beta (IL-1beta) and IL-18.

121 e that cleaves the proinflammatory cytokines interleukin-1beta (IL-1beta) and IL-18.

122 he two prominent pro-inflammatory cytokines, interleukin-1beta (IL-1beta) and IL-18.

123 tion and release of proinflammatory cytokine interleukin-1beta (IL-1beta) and macrophage pyroptosis.

124 Gingival interleukin-1beta (IL-1beta) and tumor necrosis factor a

125 and single BHB administration on hippocampal interleukin-1beta (IL-1beta) and tumor necrosis factor-a

126 The proinflammatory cytokine interleukin-1beta (IL-1beta) attracts leukocytes to site

127 Secretion of the cytokine interleukin-1beta (IL-1beta) by macrophages, a major dri

128 mokine (C-C motif) ligand 3 (CCL3) and human interleukin-1beta (IL-1beta) expression was detected in

129 cent reports demonstrated a crucial role for interleukin-1beta (IL-1beta) in osteomyelitis, but delet

130 crevicular fluid (GCF) inflammatory mediator interleukin-1beta (IL-1beta) in patients receiving regul

131 mechanism employed by HSV-1 is retention of interleukin-1beta (IL-1beta) in the intracellular space,

132 Animal and human studies have implicated interleukin-1beta (IL-1beta) in this disease.

133 ng synthesis of the proinflammatory cytokine interleukin-1beta (IL-1beta) independently of hyperglyce

134 Interleukin-1beta (IL-1beta) is a highly inflammatory cy

135 Interleukin-1beta (IL-1beta) is a proinflammatory cytoki

136 Interleukin-1beta (IL-1beta) is an inflammatory cytokine

137 Interleukin-1beta (IL-1beta) is one of the key pro-infla

138 The proinflammatory cytokine interleukin-1beta (IL-1beta) is synthesized as a non-act

139 ental TAA models are limited and the role of interleukin-1beta (IL-1beta) is undetermined.

140 l crevicular fluid (GCF) was quantified, and interleukin-1beta (IL-1beta) levels were determined in G

141 Induction of a proinflammatory cytokine, interleukin-1beta (IL-1beta) plays a role in memory impa

142 ncluding toll-like receptor 4 (TLR4) and the interleukin-1beta (IL-1beta) processing complex known as

143 MCC950 reduced interleukin-1beta (IL-1beta) production in vivo and atte

144 between the monoclonal protein and increased interleukin-1beta (IL-1beta) production, although intere

145 ces NLRC4 (NOD-like receptor C4) activation, interleukin-1beta (IL-1beta) production, and host tissue

146 hat avirulent C. burnetii triggers sustained interleukin-1beta (IL-1beta) production.

147 l cells resulted in increased cell death and interleukin-1beta (IL-1beta) production.

148 rabilis induces NLRP3 inflammasome-dependent interleukin-1beta (IL-1beta) release from CCR2(+) Ly6C(h

149 We found that the microbiota induces interleukin-1beta (IL-1beta) release upon intestinal inj

150 okine produced by beta-cells or macrophages, interleukin-1beta (IL-1beta) represents a potential ther

151 Strikingly, the interleukin-1beta (IL-1beta) response to RSV DeltaSH inf

152 he pivotal cellular and host proinflammatory interleukin-1beta (IL-1beta) response, which enables hos

153 MCs were responding to interleukin-1beta (IL-1beta) secreted by BECs after infl

154 inflammasome activation, leading to reduced interleukin-1beta (IL-1beta) secretion and diminished ce

155 showed that four different statins increased interleukin-1beta (IL-1beta) secretion from macrophages,

156 epeat protein 3) inflammasome activation and interleukin-1beta (IL-1beta) secretion in macrophages.

157 lating lipopolysaccharide and NLRP3-mediated interleukin-1beta (IL-1beta) secretion.

158 LRC4 inflammasome and caspase-1 generates an interleukin-1beta (IL-1beta) signal that is required for

159 udy, we show transient induction of Wnt5a by interleukin-1beta (IL-1beta) stimulation proceeds throug

160 dies indicate that pro-inflammatory cytokine interleukin-1beta (IL-1beta) that is up-regulated follow

161 r tumor necrosis factor alpha (TNF-alpha) or interleukin-1beta (IL-1beta) treatment.

162 ntaining a CARD domain)-dependent release of interleukin-1beta (IL-1beta) when cultured with human TH

163 Interleukin-1beta (IL-1beta), an inflammatory cytokine a

164 f inflammatory stimuli, including endotoxin, interleukin-1beta (IL-1beta), and IL-6.

165 ines tumor necrosis factor alpha (TNFalpha), interleukin-1beta (IL-1beta), and interferon gamma (IFNg

166 asured by cleavage of the enzyme, release of interleukin-1beta (IL-1beta), and pyroptosis in LPS-acti

167 tumor necrosis factor alpha (TNF-alpha), and interleukin-1beta (IL-1beta), and scores on the Multidim

168 There is a strong link between integrins and interleukin-1beta (IL-1beta), but the specifics of the r

169 cells, constitute the predominant source of interleukin-1beta (IL-1beta), IL-10, and tumor necrosis

170 nes tumor necrosis factor alpha (TNF-alpha), interleukin-1beta (IL-1beta), IL-6, IL-10, and IL-12 by

171 tion of proinflammatory cytokines, including interleukin-1beta (IL-1beta), IL-6, IL-12/23(p40), tumor

172 ciated with macrophage activation, including interleukin-1beta (IL-1beta), IL-6, IL-8, CCL20, macroph

173 igh-sensitivity C-reactive protein (hs-CRP), interleukin-1beta (IL-1beta), IL-6, tumor necrosis facto

174 tokines tumor necrosis-alpha (TNF-alpha) and interleukin-1beta (IL-1beta), may exacerbate vascular da

175 e found in HSV-1-infected WT mice, including interleukin-1beta (IL-1beta), platelet-derived growth fa

176 tumor necrosis factor alpha (TNF-alpha) and interleukin-1beta (IL-1beta), suggesting the presence of

177 flammasome, leading to a rapid production of interleukin-1beta (IL-1beta), which sustains neutrophil

178 tumor necrosis factor alpha (TNF-alpha), and interleukin-1beta (IL-1beta), without enhanced parasite

179 Caspase-1, also known as interleukin-1beta (IL-1beta)-converting enzyme (ICE), re

180 Type I interferon restrains interleukin-1beta (IL-1beta)-driven inflammation in macr

181 n and mevalonate kinase (MVK) cause distinct interleukin-1beta (IL-1beta)-mediated autoinflammatory d

182 ated NLRP3 inflammasomes have been linked to interleukin-1beta (IL-1beta)-mediated tumorigenesis in h

183 ytes expressed the pro-inflammatory cytokine interleukin-1beta (IL-1beta).

184 of caspase-1 and a proinflammatory cytokine, interleukin-1beta (IL-1beta).

185 udes release of the proinflammatory cytokine interleukin-1beta (IL-1beta).

186 e processing of the proinflammatory cytokine interleukin-1beta (IL-1beta).

187 flammasome complex to process cytokines like interleukin-1beta (IL-1beta).

188 markers, including elevated plasma levels of interleukin-1beta (IL-1beta).

189 f tumor necrosis factor-alpha (TNFalpha) and interleukin-1beta (IL-1beta).

190 r stress, and they trigger the maturation of interleukin-1beta (IL-1beta).

191 with proinflammatory cytokines, specifically interleukin-1beta (IL-1beta).

192 tumor necrosis factor alpha (TNF-alpha) and interleukin-1beta (IL-1beta).

193 recognize the structurally diverse cytokines interleukin-1beta (IL-1beta, beta-sheet) and interleukin

194 the proinflammatory response in macrophages (interleukin 1beta [IL-1beta] and tumor necrosis factor a

195 Notably, genes (IFI16, caspase-1, and interleukin 1beta [IL-1beta]) in the canonical pyroptosi

196 nal immunopathology (neutrophil recruitment, interleukin-1beta [IL-1beta] secretion, and lactate dehy

197 tumor necrosis factor alpha [TNF-alpha], and interleukin-1beta [IL-1beta]) and significantly higher l

198 reased inflammation-related gene expression (interleukin-1beta [IL-1beta]), the mRNA levels of the ab

199 anulocyte colony-stimulating factor [G-CSF], interleukin-1beta [IL-1beta], and IL-10).

200 pathway linking inflammation and depression (interleukin-1beta [Il-1beta], CD11b, IkappaBalpha, indol

201 ptosis, and proinflammatory gene expression (interleukin-1beta [IL-1beta], tumor necrosis factor-alph

202 s responses to a physical stressor (systemic interleukin-1beta; IL-1beta) in adulthood, compared with

203 ase 1, Dpp4, nitric oxide synthase 2 (Nos2), interleukin 1beta (Il1b), and matrix metalloproteinase 9

204 es (controls) and analyzed expression NLRP3, interleukin 1beta (IL1B, in plasma), and IL18 (in plasma

205 ted with polymorphisms in the genes encoding interleukin 1beta (IL1B; rs16944; recessive mode, P = .0

206 onary epithelial A549 cells, we confirm that interleukin-1beta (IL1B) induces expression of dual-spec

207 hasone-induced repression of MAPKs, 14 of 46 interleukin-1beta (IL1B)-induced mRNAs were significantl

208 enes induced, in a MAPK-dependent manner, by interleukin-1beta (IL1B).

209 Conceptus production of a unique interleukin 1beta, IL1B2, temporally increases during th

210 Levels of interleukin 1beta (IL1beta) emerged as a correlate of ad

211 riate analyses adjusting for covariates IL6, interleukin 1beta (IL1beta), and interleukin 1Ralpha (IL

212 TNFalpha), essentially failed to up-regulate interleukin-1beta (IL1beta) and did not initiate synthes

213 fish and increased secretion of the cytokine interleukin 1beta in a T3SS-dependent manner.

214 ssion of NLRP3, active caspase-1, and mature interleukin-1beta in human peripheral blood mononuclear

215 h ATP, led to an activation of caspase 1 and interleukin-1beta in P2X7-competent macrophages.

216 upstream mechanisms leading to production of interleukin-1beta in rheumatoid arthritis is limited by

217 ient ob/ob mice or by neutralizing leptin or interleukin-1beta in the NAc without diminishing morphin

218 Furthermore, we observed increased levels of interleukin-1beta in the plasma of burned patients when

219 CARD), IL-18 (Interleukin-18) and IL-1beta (Interleukin- 1Beta) in obese subjects (BMI >/= 35) with

220 hows that soluble danger signals, among them interleukin-1beta, increase bone marrow hematopoietic st

221 tory protein 2, tumor necrosis factor alpha, interleukin-1beta, inducible nitric oxide synthase, inte

222 or TGF-betaRII was strongly increased in the interleukin-1beta inflamed cremaster.

223 (CANTOS), a randomised trial of the role of interleukin-1beta inhibition in atherosclerosis, with th

224 atory therapy with canakinumab targeting the interleukin-1beta innate immunity pathway could signific

225 (qRT-PCR), and the proinflammatory cytokines interleukin 1beta, interferon beta, and RANTES (regulate

226 ealed increased transcriptional induction of interleukin 1beta, interferon beta, and RANTES in ZIKV-i

227 cytokines/chemokines in the brain, including interleukin-1beta, interferon-gamma, and fractalkine as

228 ed the large amount of heterogeneity between interleukin 1beta, interleukin 6, and C-reactive protein

229 tion of proinflammatory cytokines, including interleukin 1beta, interleukin 6, and interleukin 8, and

230 terferon gamma, tumor necrosis factor alpha, interleukin 1beta, interleukin 6, and multiple chemokine

231 evels of proinflammatory cytokines including interleukin 1beta, interleukin 6, and tumor necrosis fac

232 elial cells (ie, expression of CCL20, hBD-2, interleukin 1beta, interleukin 6, interleukin 8, and tum

233 rom A549 lung epithelial cells but decreased interleukin 1beta, interleukin 6, interleukin 8, interle

234 tumor necrosis factor-alpha, interleukin-6, interleukin-1beta, interleukin-10, and transforming grow

235 Level of interleukin-1beta, interleukin-2, interleukin-4, interle

236 tory cytokines (tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, and granulocyte macrop

237 ors tumor necrosis factor-alpha, arginase-2, interleukin-1beta, interleukin-6, and interferon-gamma.

238 brospinal fluid tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, and interleukin-8 leve

239 rospinal fluid tumor necrosis factor -alpha, interleukin-1beta, interleukin-6, and interleukin-8 leve

240 and bronchoalveolar lavage concentrations of interleukin-1beta, interleukin-6, interleukin-8, interle

241 Tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, interleukin-8, transfo

242 elease of proinflammatory cytokines, such as interleukin-1beta, interleukin-6, macrophage inflammator

243 n a dose-dependent increase in CSF levels of interleukin-1beta, interleukin-6, tumor necrosis factor

244 ssive up-regulation of proinflammatory genes interleukin-1beta, interleukin-6, tumor necrosis factor-

245 gens of red and orange complexes and a lower interleukin-1beta/interleukin-10 ratio than the control

246 n in the tumour microenvironment mediated by interleukin 1beta is hypothesised to have a major role i

247 P3 inflammasome and subsequent generation of interleukin 1beta is initiated in macrophages upon recog

248 Interleukin-1beta is a potent pro-inflammatory cytokine

249 ness duration was positively associated with interleukin 1beta levels (b=0.33, p<0.0001) and severity

250 rone in mice resulted in elevation of plasma interleukin-1beta levels and vascular abnormalities.

251 lymorphonuclear leukocyte (PMN), S100A8, and interleukin-1beta levels obtained from vaginal lavage fl

252 d beta2, vascular endothelial growth factor, interleukin-1beta, matrix metalloproteinase-1, versican,

253 The NLRP3 inflammasome controls interleukin-1beta maturation in antigen-presenting cells

254 tial for caspase-11-dependent pyroptosis and interleukin-1beta maturation.

255 optosis proteins, proinflammatory cytokines (interleukin-1beta, monocyte chemoattractant protein-1, a

256 a, and liver tumor necrosis factor-alpha and interleukin 1beta mRNA were evaluated.

257 nprenylated RhoA produce increased levels of interleukin 1beta mRNA.

258 isting velocity by speckle tracking; and (4) interleukin-1beta, nitrotyrosine, malondialdehyde, prote

259 infected with virus or exposed to IFN-gamma/interleukin-1beta or IFN-alpha.

260 Schwann cells, and neural fibers; increased interleukin-1beta (P = 0.004), tumor necrosis factor-alp

261 tokine associated with keratoconjunctivitis, interleukin-1beta (P = 0.025), in their ocular surface e

262 SC), to catalyze proteolytic cleavage of pro-interleukin-1beta (pro-IL-1beta) and pro-IL-18 and drive

263 and maturation of inflammatory cytokines pro-interleukin-1beta (pro-IL-1beta) and pro-IL-18.

264 e caspase-11, causing pyroptotic cell death, interleukin-1beta processing, and lethal septic shock.

265 thogenesis through Rac1/PKB signaling toward interleukin 1beta production and elucidate the effects o

266 lung epithelial cells was shown to regulate interleukin-1beta promoter activity.

267 expression, caspase 1 activity, or IL-1beta (interleukin-1beta) protein expression under in vivo and

268 aseline, patients with CAD had 3-fold higher interleukin-1beta, protein carbonyl, higher nitrotyrosin

269 Importance: Anakinra, an interleukin 1beta recombinant receptor antagonist, may h

270 aortic aneurysm formation, neutralization of interleukin-1beta reduced arterial wall stiffness and ha

271 e CNS, Rag1(-/-) mice showed lower levels of interleukin 1beta, reduced microglial proliferation, and

272 Canakinumab, a monoclonal antibody targeting interleukin-1beta, reduces inflammation and cardiovascul

273 in complexes that regulate maturation of the interleukin 1beta-related cytokines IL-1beta and IL-18 t

274 roglial activation and inflammasome-mediated interleukin 1beta release that contributes to neuroinfla

275 rreversible NLRP3 inhibitor able to decrease interleukin-1beta release from macrophages.

276 Control of interleukin-1beta release is vital as excessively high s

277 roptosis, as measured by caspase-1-dependent interleukin-1beta release, though this phenotype could b

278 ure, rho = 0.68, P = 0.04) and inflammation (interleukin-1beta, rho = -0.80, P = 0.009).

279 itro, aldosterone stimulated NLRP3-dependent interleukin-1beta secretion by bone marrow-derived macro

280 ediated caspase-1 activation, pyroptosis and interleukin-1beta secretion by soluble and crystalline N

281 geting also exhibit defective pyroptosis and interleukin-1beta secretion induced by cytoplasmic lipop

282 +) T cells and initiates caspase-1-dependent interleukin-1beta secretion, thereby promoting interfero

283 other major readout of caspase-1 activation, interleukin-1beta secretion.

284 d an increase in NLRP3 inflammasome-mediated interleukin-1beta secretion.

285 Interleukin 6 (SMD 0.88; p=0.0003), interleukin 1beta (SMD 1.42; p=0.045), and interferon ga

286 TNFalpha (SMD 1.32, 0.13-2.50; p=0.003), interleukin 1beta (SMD 2.35, 0.01-4.68; p=0.048), and in

287 versus non-spinal cord injury group, whereas interleukin-1beta, soluble interleukin-2 receptor-alpha,

288 7F, without effects on interleukin 1alpha or interleukin 1beta, suggesting a disturbance in interleuk

289 An antibody that neutralizes interleukin-1beta suppresses these effects.

290 p110delta exhibited constitutive release of interleukin 1beta that was dependent on MEFV but indepen

291 Here, we reported that in response to interleukin 1beta, the p65 subunit of NF-kappaB is phosp

292 tory and produce robust amounts of IL-1beta (interleukin-1beta) through the non-canonical caspase-11

293 is associated with increased interleukin 6, interleukin 1beta, TNFalpha, and interferon gamma levels

294 Anti-interleukin-1beta treatment dampens the post-MI increase

295 inical attachment level, gingival recession, interleukin-1beta, tumor necrosis factor (TNF)-alpha, an

296 ZDF islets contain elevated levels of CB1R, interleukin-1beta, tumor necrosis factor-alpha, the chem

297 ver, unlike TNF-alpha, the secreted level of interleukin 1beta was not affected by coculture with DPS

298 , as well as tumor necrosis factor-alpha and interleukin-1beta, were significantly increased in colon

299 nced expression of the inflammatory cytokine interleukin-1beta, when compared to mice with intact CX3

300 ma levels of tumor necrosis factor-alpha and interleukin-1beta while cardiac function was significant